Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis

Yoon Jee Lee, JaeHee Cheon, Jae Hyun Kim, Sunho Yoo, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). Materials and Methods: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. Results: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). Conclusion: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.

Original languageEnglish
Pages (from-to)144-149
Number of pages6
JournalYonsei medical journal
Volume58
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Beclomethasone
Ulcerative Colitis
Therapeutics
Safety
Medical Records
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Yoon Jee ; Cheon, JaeHee ; Kim, Jae Hyun ; Yoo, Sunho ; Lee, Hyun Jung ; Park, Soo Jung ; Hong, Sung Pil ; Kim, Tae Il ; Kim, Won Ho. / Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis. In: Yonsei medical journal. 2017 ; Vol. 58, No. 1. pp. 144-149.
@article{02c8134e03b9444097019739009ce935,
title = "Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis",
abstract = "Purpose: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). Materials and Methods: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30{\%} from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. Results: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5{\%} and 73.7{\%}, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7{\%}) than that in the moderate or severe disease activity group (41.9{\%}) (p=0.024). Conclusion: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.",
author = "Lee, {Yoon Jee} and JaeHee Cheon and Kim, {Jae Hyun} and Sunho Yoo and Lee, {Hyun Jung} and Park, {Soo Jung} and Hong, {Sung Pil} and Kim, {Tae Il} and Kim, {Won Ho}",
year = "2017",
month = "1",
day = "1",
doi = "10.3349/ymj.2017.58.1.144",
language = "English",
volume = "58",
pages = "144--149",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

Lee, YJ, Cheon, J, Kim, JH, Yoo, S, Lee, HJ, Park, SJ, Hong, SP, Kim, TI & Kim, WH 2017, 'Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis', Yonsei medical journal, vol. 58, no. 1, pp. 144-149. https://doi.org/10.3349/ymj.2017.58.1.144

Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis. / Lee, Yoon Jee; Cheon, JaeHee; Kim, Jae Hyun; Yoo, Sunho; Lee, Hyun Jung; Park, Soo Jung; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho.

In: Yonsei medical journal, Vol. 58, No. 1, 01.01.2017, p. 144-149.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis

AU - Lee, Yoon Jee

AU - Cheon, JaeHee

AU - Kim, Jae Hyun

AU - Yoo, Sunho

AU - Lee, Hyun Jung

AU - Park, Soo Jung

AU - Hong, Sung Pil

AU - Kim, Tae Il

AU - Kim, Won Ho

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). Materials and Methods: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. Results: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). Conclusion: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.

AB - Purpose: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). Materials and Methods: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. Results: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). Conclusion: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.

UR - http://www.scopus.com/inward/record.url?scp=84995810078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995810078&partnerID=8YFLogxK

U2 - 10.3349/ymj.2017.58.1.144

DO - 10.3349/ymj.2017.58.1.144

M3 - Article

VL - 58

SP - 144

EP - 149

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -